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Background: Cachexia, a >10% loss of body-weight, is one factor determining the poor prognosis of pancreatic
cancer. Deficiency of L-Carnitine has been proposed to cause cancer cachexia.
Findings: We screened 152 and enrolled 72 patients suffering from advanced pancreatic cancer in a prospective,
multi-centre, placebo-controlled, randomized and double-blinded trial to receive oral L-Carnitine (4 g) or placebo
for 12 weeks. At entry patients reported a mean weight loss of 12 ± 2,5 (SEM) kg. During treatment body-mass-
index increased by 3,4 ± 1,4% under L-Carnitine and decreased (−1,5 ± 1,4%) in controls (p< 0,05). Moreover,
nutritional status (body cell mass, body fat) and quality-of-life parameters improved under L-Carnitine. There was a
trend towards an increased overall survival in the L-Carnitine group (median 519 ± 50 d versus 399 ± 43 d, not
significant) and towards a reduced hospital-stay (36 ± 4d versus 41 ± 9d,n.s.).
Conclusion: While these data are preliminary and need confirmation they indicate that patients with pancreatic
cancer may have a clinically relevant benefit from the inexpensive and well tolerated oral supplementation of
L-Carnitine.
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Adenocarcinoma of the pancreas is highly resistant to
chemo- or radiotherapy [1], has a 5-year survival rate
of only 4% and ranks as fourth leading cause of cancer
death [2–4]. One reason contributing to this high mor-
tality is cancer cachexia, defined as an unintended
weight loss of more than 10% in 6 months, which is
present in more than 80% of pancreatic cancer patients
[5]. Cancer cachexia is also a predictor for reduced
quality of life, increased mortality, and poor response
to therapy [6–10]. A deficiency of L-Carnitine has been
proposed to be an underlying cause of cancer cach-
exia [11] and tumor associated fatigue [12–14]. Al-
though L-Carnitine can be generated via endogenous* Correspondence: lerch@unireifswald.de
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reproduction in any medium, provided the orconversion from lysine and methionine, 75% of the
required levels are provided from food sources. In vitro
studies in human tumor cell lines have shown a posi-
tive effect of L-Carnitine regarding the inhibition of
apoptosis and DNA-damage [15]. On the other hand,
L-Carnitine is well known for its potential to modulate
the inflammatory response mechanisms, which is
known to play the predominant role in the generation
of cancer cachexia, especially in pancreatic tumor
patients [16]. We therefore conducted a multicentre
trial to investigate the role of oral L-Carnitine supple-
mentation on cancer cachexia in pancreatic cancer
(CARPAN).Methods
Patients from 4 participating tertiary referral centers were
considered eligible for inclusion when they had histologi-
cally proven, advanced and irresectable adenocarcinomad. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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formance status of >60 and declared their written
informed consent to participate. The CARPAN protocol
was approved by the ethics committee of Greifswald Uni-
versity (Reg.Nr.IIIUV73/05) and registered at clinical-
trials.gov (NCT01330823) and under ISRCTN83465351.
Patients were recruited regardless of concomitant or
scheduled chemotherapy. Exclusion criteria were liver
failure, a second malignancy, treatment with omega-3-
fatty acids and the presence of a mental disorder preclud-
ing informed consent. From May 2006 until October
2009 a total of 152 patients were screened and 72 en-
rolled in the study (Figure 1). Reasons for non-
enrollment were mostly due to poor performance status
or withheld consent. Patients were randomized (sequen-
tial series of 4 per block, sealed envelopes, computer
generated randomization code) to receive either an oral
liquid formulation of L-Carnitine (4 g/d, obtained from
Lonza, Basel, CH) or identically formulated placebo with
follow up visits at 6 and 12 weeks after entry. Compli-
ance was tested by determining serum L-Carnitine levels
by Tandem-Mass-Spectrometry (normal range between
40–60 μmol/l) (ABI 2000, Perkin-Elmer, Turku, SF) [17].
L-Carnitine deficiency is generally believed to occur
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Figure 1 Flow chart of the trial.controversially discussed [18]. At every study visit ad-
verse events and body mass index (BMI) were recorded
and bioelectrical impedance analysis (BIA-Nutrigard-M,
Darmstadt, Germany) was used to determine body com-
position [19]. For evaluation of quality of life we used
the EORTC-QLQ-C30 questionnaire with a pancreatic
cancer specific module PAN26 [20] and for fatigue the
Brief Fatigue Inventory (BFI) questionnaire [21]. Survival
time in days was calculated from time of diagnosis to
death. Sample size calculation was based on previous
studies investigating the effect of L-Carnitine on inflam-
matory markers [22], with TNFα level differences as pri-
mary endpoint, and resulted in a recruitment goal of 90
patients (45 per treatment arm) for a statistical power of
90% with an error probability of <5%. After a presched-
uled interim analysis for sample size recalculation of 72
blinded datasets showed a wide variation of the standard
errors for inflammatory markers a recruitment of 554
patients (277 per group) would have been necessary.
Since this goal was unattainable the study was closed
after enrolment of 72 patients and the data were
unblinded for statistical analysis.
Data are presented as means ± SEM and 95% confi-
dence intervals where appropriate. Statistical analysis for
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parametric and Mann–Whitney-U-Test for non-
parametric analysis. Quality of life data were analyzed
using ANOVA. Results were considered significant
when p was <0,05.
Results
Patient characteristics are given in Table 1 and showed no
statistical difference between both groups at enrolment.
At entry 88% of patients in the placebo and 92% of
patients in the L-Carnitine group received chemotherapy.
There was no statistically significant difference between
both groups (p< 0,05). 90% of the patients reported a
weight loss of >10% during the previous 6 month. This
observation is in line with previous reports on cancer
cachexia [5]. 26 patients completed the entire follow up
period and premature drop-out was due to death
(n = 11), deteriorating health (n = 9), nausea (n = 8), ex-
cessive demand (n = 5), diarrhea (n = 2) or miscellaneous
symptoms (n = 7). Drop out rates and reasons were not
different between both treatment arms. Oral supplemen-

























No statistically significant differences were observed between L-Carnitine and place
*weight loss during the last 6 month.
**ECM/BCM-Index, Extra-Cellular-Mass/Body-Cell-Mass-Index.serum plasma levels up to 60% of the basic value at week
6 (p< 0,009) in the L-Carnitine group (Figure 2), while a
constant decline of L-Carnitine plasma levels was evident
during the observation period in the placebo group. This
might be related to tumor effects and / or due to con-
comitant chemotherapy. L-Carnitine supplementation
was well tolerated. Side effects did not differ significantly
in comparison with placebo group (predominantly nau-
sea, vomiting, and diarrhoea) and, whenever they oc-
curred, may have been caused by concomitant
chemotherapy.
Patients on L-Carnitine treatment gained weight (BMI
increase of 3.4%± 1.35)whereas patients on placebo did
not (BMI reduction of 1.5%± 1.4, p< 0.018). After
12 weeks of therapy the difference amounted to
4.9%± 1.9 (Figure 3) between groups. BIA revealed that
this improvement was due to increases in body cell mass
(BCM, p< 0,013) and body fat (BF, p< 0,041). CRP, albu-
min, leukocyte count and CA19-9 remained unaffected
(data not shown). Regarding quality of life (EORTC-
QLQ-C30/PAN26) the only significant changes were im-
provement in cognitive function (at enrolment 81,0 ± 21,5eline visit of the study (mean±SEM)
L-Carnitine (n = 38) Placebo (n = 34)
20 (52.6%) 23 (67.6%)
18 (47.4%) 11 (32.4%)
64.4 ± 1.67 64.4 ± 1.65
76.8 ± 1.87 80.0 ± 2.16
28.0 ± 1.01 30.1 ± 0.84
24.7 ± 0.65 24.9 ± 0.89
4.4 ± 0.16 4.4 ± 0.17
34 (89.5%) 31 (91.2%)
4 (10.5%) 3 (8.8%)
11.4 ± 1.28 12.3 ± 1.56
20 (52.6%) 21 (61.8%)
14 (36.8%) 9 (26.5%)
4 (10.5%) 4 (11.7%)
1.5 ± 0.11 1.4 ± 0
41.8 ± 1.22 42.70 ± 1.21
25.3 ± 2.29 24. 8 ± 2.11
33.8 ± 1.09 33.7 ± 1.20
31.3 ± 6.55 45.5 ± 10.39
8.3 ± 0.83 6.9 ± 0.46


























Figure 2 Reasons for discontinued convention of the study patients. Reasons for discontinued convention of the study patients.
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6 -weeks L- Carnitine group 0,30 versus −0,13 in the pla-
cebo group, p< 0,034), improvement of global health
status (at enrolment 53,6 ± 19,5 in L-Carnitine group,
65,3 ± 17,7 in placebo group; after 12 weeks L- Carnitine
group 0,76 versus −0,32 in the placebo group, p< 0,041)
and reduction in gastrointestinal symptoms (at enrolment
29,8± 32,1 in L-Carnitine group, 19,4± 24,5; in the placebo
group; after 12 weeks L-Carnitine group −0,35 versus 0,78





























Figure 3 Relevant nutritional parameters and survival. Relevant nutritio
treatment arm (black lines) and placebogroup (gray lines). Survival is given
(BMI), body fat, and body cell mass (BCM) aregiven as percent changes und
significant differences (p< 0.05).fatigue (moderate/severe, >4 on BFI), present in
28,6% of L-Carnitine patients versus 41,7% in the placebo
group,were not statistically significant, nor was the
survival benefit (Figure 2, median 519 ± 50d versus
399 ±43d with placebo), and the reduction in length of
hospital stay (36±4d versus 41±9d with placebo).
Conclusion
Cancer cachexia and malnutrition are associated with




































nal parameters (means± SEM) and survival in days in the L-Carnitine
in days after diagnosis as Kaplan-Meier curve and body mass index
er respective treatment over 12 weeks. Asterisks indicate statistically
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overall survival of colon cancer patients can improve
under early nutritional intervention [23]. L-Carnitine is
critical for energy generation by mitochondrial ß-
oxidation and was found depleted under chemotherapy
[24–26]. Its oral supplementation can normalize nutri-
tional L-Carnitine deficiency [27,28] and reduce chemo-
therapy related side effects [29,30]. We therefore tested
whether oral L-Carnitine supplementation has a clinical
benefit in patients with advanced pancreatic cancer and
found that L-Carnitine can reduce malnutrition, increase
bodyweight and improve body composition.
When we planned and designed the study no persuasive
data for clinical endpoints existed and we had to base the
initial power calculations on inflammatory markers in
humans under L-Carnitine treatment. While this study
must be regarded as preliminary because inflammatory
markers were found to be an unsuitable primary endpoint
in our setting, the CARPAN trial provides the basis for
a robust sample size calculation: a conclusive study of
L-Carnitine benefits ought to enrol 148 patients in each
arm to show a survival benefit with 90% power, and
would need 157 patients in each arm to demonstrate an
improvement in tumor fatigue. The presently available
data show a benefit of L-Carnitine supplementation on
body weight, body composition and some aspects of
quality-of-life, even though it was underpowered to de-
termine the statistical significance of other secondary
endpoints. While the loss of significant changes in BCM
at week 12 and a rapid increase in body fat between
week 6 and 12 was an unexpected finding it might be
explained by the underlying progressive tumor disease
leading to changes in body composition, irrespective of
gain of weight and due to reduced physical activity and
progressive sarcopenia. Both are common findings in
pancreatic tumors. In this context it is important to
note, that the direct influence of L-Carnitine on tumor
growth has not been measured in this study and is be-
yond the scope of this work. Future studies are needed
to address this question as only recently L-Carnitine has
been reported to modify apoptosis and DNA-damage in
tumor cell lines of the brain via CPT-1 C [15].
The CARPAN trial could suggest that the clinical
benefit of an inexpensive and very well tolerated oral
L-Carnitine supplementation may reach the clinical
benefit level previously shown for palliative Gemcita-
bine chemotherapy [31] in pancreatic cancer patients.
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